Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer.

Trial Profile

A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2019

At a glance

  • Drugs Darolutamide (Primary) ; Enzalutamide
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ODENZA Preference
  • Most Recent Events

    • 05 Feb 2019 According to a Bayer media release, data from this trial will be presented at the 2019 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February 14-16 in San Francisco.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 25 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top